Tarikere L. Gururaja
Rigel Pharmaceuticals
Incorporated
1180 Veterans Boulevard
South San Francisco
USA
Name/email consistency: high
- A class of small molecules that inhibit TNFalpha-induced survival and death pathways via prevention of interactions between TNFalphaRI, TRADD, and RIP1. Gururaja, T.L., Yung, S., Ding, R., Huang, J., Zhou, X., McLaughlin, J., Daniel-Issakani, S., Singh, R., Cooper, R.D., Payan, D.G., Masuda, E.S., Kinoshita, T. Chem. Biol. (2007)
- R-253 disrupts microtubule networks in multiple tumor cell lines. Gururaja, T.L., Goff, D., Kinoshita, T., Goldstein, E., Yung, S., McLaughlin, J., Pali, E., Huang, J., Singh, R., Daniel-Issakani, S., Hitoshi, Y., Cooper, R.D., Payan, D.G. Clin. Cancer Res. (2006)
- Utility of peptide-protein affinity complexes in proteomics: identification of interaction partners of a tumor suppressor peptide. Gururaja, T.L., Li, W., Payan, D.G., Anderson, D.C. J. Pept. Res. (2003)









